Links between diabetes and obesity treatment drugs and sudden pancreas and bile duct problems

No significant risk differences were found for acute pancreatitis or biliary disease in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA) compared to sodium-glucose cotransporter 2 inhibitors (SGLT-2i).

• The hazard ratio for acute pancreatitis in patients treated with GLP-1 RA was 0.56, indicating no increased risk.
• The hazard ratio for biliary disease was 1.12, suggesting no significant difference in risk between the two treatment groups.
• Secondary analyses confirmed the lack of risk differences for both acute pancreatitis and biliary disease.
• Adherence to approved treatment indications and monitoring for adverse events is recommended for patient safety.

Simplified